Product Description
The research-grade biosimilar is a recombinant antibody to Mirvetuximab without the drug conjugation. The original antibody-drug conjugate (Mirvetuximab soravtansine) consists of an anti-FOLR1 humanized antibody conjugated to DM4, an anti-tumor chemical derivative of maytansine via a disulfide-containing cleavable sulfo-SPDB linker. Upon interaction and internalization by FOLR1 expressing tumor cells, the DM4 is detached from the antibody due to proteolytic cleavage. The DM4 then inhibits polymerization of the tubulin and assembly of the microtubules, thus resulting in cell cycle arrest and apoptosis. The original antibody-drug conjugate is used as an investigational agent to treat a variety of cancers such as ovarian, endometrial, fallopian tube, epithelial ovarian, and primary peritoneal cancer
Biovision | A2271 | Anti-FOLR1 (Mirvetuximab), Humanized Antibody DataSheet
Antibody Target: FOLR1
Target Alternative Name: FBP, FOLR, NCFTD, FRalpha, FOLR1, Folate Receptor 1 (Adult), KB Cells FBP, FR-Alpha, FR?
Tag Line: The biosimilar is a humanized antibody that targets Folate receptor 1 (FOLR1)
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human FOLR1
Accession #: DB16235
Gene ID: 2348
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE